United States - English - NLM (National Library of Medicine)

fresenius kabi usa, llc - kanamycin a sulfate (unii: j80ex28smq) (kanamycin a - unii:eqk9q303c5) - kanamycin a 333 mg in 1 ml

Malta - English - Medicines Authority

ursapharm arzeneitmittel gmbh industriestrasse, 66129 saarbrucken, germany - kanamycin monosulphate - eye drops - kanamycin monosulphate 6.2 mg/ml - ophthalmologicals

Malta - English - Medicines Authority

ursapharm arzeneitmittel gmbh industriestrasse, 66129 saarbrucken, germany - kanamycin monosulphate - eye ointment - kanamycin monosulphate 6.2 mg/g - ophthalmologicals

Japan - English - すりの適正使用協議会 RAD-AR Council, Japan

meiji seika pharma co., ltd. - kanamycin monosulfate - pale yellow capsule, major axis: 19.4 mm, thickness: 6.9 mm

United States - English - NLM (National Library of Medicine)

ax pharmaceutical corp - kanamycin sulfates (unii: ow1n4g4r9w) (kanamycin - unii:ruc37xup2p) - kanamycin 4.95 kg in 5 kg

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

link healthcare sdn. bhd. - natamycin -

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

link healthcare sdn. bhd. - natamycin -

Namibia - English - Namibia Medicines Regulatory Council

biotech laboratories (pty) ltd - kanamycin sulphate - injection - each vial contains; kanamycin sulphate equivalent to kanamycin 1,000.0 mg

United States - English - NLM (National Library of Medicine)

alcon laboratories, inc. - natamycin (unii: 8o0c852cpo) (natamycin - unii:8o0c852cpo) - natacyn® (natamycin ophthalmic suspension) 5% is indicated for the treatment of fungal blepharitis, conjunctivitis, and keratitis caused by susceptible organisms including fusarium solani keratitis. as in other forms of suppurative keratitis, initial and sustained therapy of fungal keratitis should be determined by the clinical diagnosis, laboratory diagnosis by smear and culture of corneal scrapings and drug response. whenever possible the in vitro activity of natamycin against the responsible fungus should be determined. the effectiveness of natamycin as a single agent in fungal endophthalmitis has not been established. natacyn® (natamycin ophthalmic suspension) 5% is contraindicated in individuals with a history of hypersensitivity to any of its components. safety and effectiveness in pediatric patients have not been established. no overall differences in safety or effectiveness have been observed between elderly and younger patients.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

special order - natamycin - eye drops - 50mg/1ml